Milestone Pharmaceuticals (MIST) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Milestone Pharmaceuticals is gearing up for the potential FDA approval of its CARDAMYST nasal spray for PSVT, with a decision expected by March 2025. The company’s partner, Corxel, reported positive Phase 3 trial results in China, showing significant efficacy in converting PSVT to sinus rhythm. Milestone is actively preparing for a commercial launch and expanding its clinical trials to improve patient care.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
